---
document_datetime: 2025-12-25 07:00:39
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/replagal.html
document_name: replagal.html
version: success
processing_time: 0.1113908
conversion_datetime: 2025-12-27 22:03:26.51361
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Replagal

[RSS](/en/individual-human-medicine.xml/65621)

##### Authorised

This medicine is authorised for use in the European Union

agalsidase alfa Medicine Human Authorised

On Monday, 12 January 2026, between 07:00 and 10:00 CET (Amsterdam time), this website will be unavailable due to scheduled maintenance.

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [More information on Replagal](#more-information-on-replagal-482)
- [Topics](#topics)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

This is a summary of the European public assessment report (EPAR) for Replagal. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Replagal.

Expand section

Collapse section

## What is Replagal?

Replagal is medicine that contains the active substance agalsidase alfa. It is available as a concentrate to be made into solution for infusion (drip) into a vein.

## What is Replagal used for?

Replagal is used to treat patients who have Fabry disease, a rare inherited disorder. Patients with Fabry disease do not have enough of an enzyme called alpha-galactosidase A. This enzyme normally breaks down a fatty substance called globotriaosylceramide (Gb3 or GL-3). If the enzyme is not present, Gb3 cannot be broken down and it builds up in the body's cells, such as kidney cells.

People with Fabry disease may have a wide range of signs and symptoms, including severe conditions such as kidney failure, heart problems, and stroke.

The medicine can only be obtained with a prescription.

## How is Replagal used?

Only a doctor who has experience in treating patients with Fabry disease or other inherited metabolic diseases should give Replagal.

Replagal is given once every 2 weeks as an infusion of 0.2 mg per kilogram body weight over 40 minutes. It is intended for long-term use.

## How does Replagal work?

Replagal is an enzyme-replacement therapy. Enzyme-replacement therapy provides patients with the enzyme they are lacking. Replagal is designed to replace the human enzyme alpha-galactosidase A, which is lacking in people with Fabry disease. The active substance in Replagal, agalsidase alfa, is a copy of the human enzyme, produced by a method known as 'recombinant DNA technology': it is made by cells that have received a gene (DNA), which makes them able to produce the enzyme. The replacement enzyme helps to break down the Gb3 and stops it building up in the cells.

## How has Replagal been studied?

Replagal has been compared with placebo (a dummy treatment) in two main studies involving a total of 40 male patients. The first study measured the effects of Replagal on pain while the second study measured its effect on the mass of the left ventricle (heart muscle), a measure of the amount of Gb3 in the heart cells. The effect of giving doses weekly rather than every two weeks was also investigated.

A further study was carried out in 15 female patients. Replagal has also been evaluated in additional studies involving 38 children aged 7 years or above.

## What benefit has Replagal shown during the studies?

After 6 months of treatment, Replagal significantly reduced pain in patients compared with placebo.

Replagal reduced left ventricle mass by an average of 11.5 g while patients receiving placebo had an increase in left ventricular mass of 21.8 g. The effects in female patients were comparable to those in male patients and weekly dosing had no advantage over standard doses.

Children who received Replagal had no unexpected increase in heart mass, and the levels of Gb3 in their blood were reduced.

## What is the risk associated with Replagal?

The most common side effects with Replagal (seen in more than 1 patient in 10) are infusion-associated reactions. These include chills, headache, nausea, pyrexia (fever), pain and discomfort, flushing and fatigue (tiredness), and are rarely severe. For the full list of all side effects and restrictions with Replagal, see the package leaflet.

## Why has Replagal been approved?

The CHMP decided that for patients with Fabry disease treatment with Replagal might provide long-term clinical benefits. The CHMP decided that Replagal's benefits are greater than its risks and recommended that it be given marketing authorisation.

Replagal was originally authorised under 'exceptional circumstances', because as the disease is rare, limited information was available at the time of approval. As the company had supplied the additional information requested, the 'exceptional circumstances' ended on 20 July 2015.

## Other information about Replagal

The European Commission granted a marketing authorisation valid throughout the European Union for Replagal on 3 August 2001.

For more information about treatment with Replagal, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.

Replagal : EPAR - Summary for the public

English (EN) (82.69 KB - PDF)

**First published:** 12/04/2007

**Last updated:** 29/07/2015

[View](/en/documents/overview/replagal-epar-summary-public_en.pdf)

[Other languages (22)](#file-language-dropdown-287)

български (BG) (116.76 KB - PDF)

**First published:**

12/04/2007

**Last updated:**

29/07/2015

[View](/bg/documents/overview/replagal-epar-summary-public_bg.pdf)

español (ES) (80.81 KB - PDF)

**First published:**

12/04/2007

**Last updated:**

29/07/2015

[View](/es/documents/overview/replagal-epar-summary-public_es.pdf)

čeština (CS) (101.79 KB - PDF)

**First published:**

12/04/2007

**Last updated:**

29/07/2015

[View](/cs/documents/overview/replagal-epar-summary-public_cs.pdf)

dansk (DA) (80.01 KB - PDF)

**First published:**

12/04/2007

**Last updated:**

29/07/2015

[View](/da/documents/overview/replagal-epar-summary-public_da.pdf)

Deutsch (DE) (81.51 KB - PDF)

**First published:**

12/04/2007

**Last updated:**

29/07/2015

[View](/de/documents/overview/replagal-epar-summary-public_de.pdf)

eesti keel (ET) (79.89 KB - PDF)

**First published:**

12/04/2007

**Last updated:**

29/07/2015

[View](/et/documents/overview/replagal-epar-summary-public_et.pdf)

ελληνικά (EL) (105.48 KB - PDF)

**First published:**

12/04/2007

**Last updated:**

29/07/2015

[View](/el/documents/overview/replagal-epar-summary-public_el.pdf)

français (FR) (81.54 KB - PDF)

**First published:**

12/04/2007

**Last updated:**

29/07/2015

[View](/fr/documents/overview/replagal-epar-summary-public_fr.pdf)

hrvatski (HR) (96.82 KB - PDF)

**First published:**

12/04/2007

**Last updated:**

29/07/2015

[View](/hr/documents/overview/replagal-epar-summary-public_hr.pdf)

italiano (IT) (80.46 KB - PDF)

**First published:**

12/04/2007

**Last updated:**

29/07/2015

[View](/it/documents/overview/replagal-epar-summary-public_it.pdf)

latviešu valoda (LV) (98.68 KB - PDF)

**First published:**

12/04/2007

**Last updated:**

29/07/2015

[View](/lv/documents/overview/replagal-epar-summary-public_lv.pdf)

lietuvių kalba (LT) (97.71 KB - PDF)

**First published:**

12/04/2007

**Last updated:**

29/07/2015

[View](/lt/documents/overview/replagal-epar-summary-public_lt.pdf)

magyar (HU) (95.73 KB - PDF)

**First published:**

12/04/2007

**Last updated:**

29/07/2015

[View](/hu/documents/overview/replagal-epar-summary-public_hu.pdf)

Malti (MT) (101.51 KB - PDF)

**First published:**

12/04/2007

**Last updated:**

29/07/2015

[View](/mt/documents/overview/replagal-epar-summary-public_mt.pdf)

Nederlands (NL) (80.46 KB - PDF)

**First published:**

12/04/2007

**Last updated:**

29/07/2015

[View](/nl/documents/overview/replagal-epar-summary-public_nl.pdf)

polski (PL) (100.26 KB - PDF)

**First published:**

12/04/2007

**Last updated:**

29/07/2015

[View](/pl/documents/overview/replagal-epar-summary-public_pl.pdf)

português (PT) (81.07 KB - PDF)

**First published:**

12/04/2007

**Last updated:**

29/07/2015

[View](/pt/documents/overview/replagal-epar-summary-public_pt.pdf)

română (RO) (97.72 KB - PDF)

**First published:**

12/04/2007

**Last updated:**

29/07/2015

[View](/ro/documents/overview/replagal-epar-summary-public_ro.pdf)

slovenčina (SK) (101.15 KB - PDF)

**First published:**

12/04/2007

**Last updated:**

29/07/2015

[View](/sk/documents/overview/replagal-epar-summary-public_sk.pdf)

slovenščina (SL) (87.16 KB - PDF)

**First published:**

12/04/2007

**Last updated:**

29/07/2015

[View](/sl/documents/overview/replagal-epar-summary-public_sl.pdf)

Suomi (FI) (80.39 KB - PDF)

**First published:**

12/04/2007

**Last updated:**

29/07/2015

[View](/fi/documents/overview/replagal-epar-summary-public_fi.pdf)

svenska (SV) (80.32 KB - PDF)

**First published:**

12/04/2007

**Last updated:**

29/07/2015

[View](/sv/documents/overview/replagal-epar-summary-public_sv.pdf)

## Product information

Replagal : EPAR - Product Information

English (EN) (291.18 KB - PDF)

**First published:** 03/11/2008

**Last updated:** 19/12/2025

[View](/en/documents/product-information/replagal-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-403)

български (BG) (357.27 KB - PDF)

**First published:**

03/11/2008

**Last updated:**

19/12/2025

[View](/bg/documents/product-information/replagal-epar-product-information_bg.pdf)

español (ES) (276.9 KB - PDF)

**First published:**

03/11/2008

**Last updated:**

19/12/2025

[View](/es/documents/product-information/replagal-epar-product-information_es.pdf)

čeština (CS) (336.81 KB - PDF)

**First published:**

03/11/2008

**Last updated:**

19/12/2025

[View](/cs/documents/product-information/replagal-epar-product-information_cs.pdf)

dansk (DA) (275.75 KB - PDF)

**First published:**

03/11/2008

**Last updated:**

19/12/2025

[View](/da/documents/product-information/replagal-epar-product-information_da.pdf)

Deutsch (DE) (284.71 KB - PDF)

**First published:**

03/11/2008

**Last updated:**

19/12/2025

[View](/de/documents/product-information/replagal-epar-product-information_de.pdf)

eesti keel (ET) (271.12 KB - PDF)

**First published:**

03/11/2008

**Last updated:**

19/12/2025

[View](/et/documents/product-information/replagal-epar-product-information_et.pdf)

ελληνικά (EL) (373.13 KB - PDF)

**First published:**

03/11/2008

**Last updated:**

19/12/2025

[View](/el/documents/product-information/replagal-epar-product-information_el.pdf)

français (FR) (338.13 KB - PDF)

**First published:**

03/11/2008

**Last updated:**

19/12/2025

[View](/fr/documents/product-information/replagal-epar-product-information_fr.pdf)

hrvatski (HR) (322.08 KB - PDF)

**First published:**

03/11/2008

**Last updated:**

19/12/2025

[View](/hr/documents/product-information/replagal-epar-product-information_hr.pdf)

íslenska (IS) (282.81 KB - PDF)

**First published:**

03/11/2008

**Last updated:**

19/12/2025

[View](/is/documents/product-information/replagal-epar-product-information_is.pdf)

italiano (IT) (283.05 KB - PDF)

**First published:**

03/11/2008

**Last updated:**

19/12/2025

[View](/it/documents/product-information/replagal-epar-product-information_it.pdf)

latviešu valoda (LV) (332.73 KB - PDF)

**First published:**

03/11/2008

**Last updated:**

19/12/2025

[View](/lv/documents/product-information/replagal-epar-product-information_lv.pdf)

lietuvių kalba (LT) (329.38 KB - PDF)

**First published:**

03/11/2008

**Last updated:**

19/12/2025

[View](/lt/documents/product-information/replagal-epar-product-information_lt.pdf)

magyar (HU) (335.34 KB - PDF)

**First published:**

03/11/2008

**Last updated:**

19/12/2025

[View](/hu/documents/product-information/replagal-epar-product-information_hu.pdf)

Malti (MT) (350.37 KB - PDF)

**First published:**

03/11/2008

**Last updated:**

19/12/2025

[View](/mt/documents/product-information/replagal-epar-product-information_mt.pdf)

Nederlands (NL) (302.76 KB - PDF)

**First published:**

03/11/2008

**Last updated:**

19/12/2025

[View](/nl/documents/product-information/replagal-epar-product-information_nl.pdf)

norsk (NO) (278.87 KB - PDF)

**First published:**

03/11/2008

**Last updated:**

19/12/2025

[View](/no/documents/product-information/replagal-epar-product-information_no.pdf)

polski (PL) (343.63 KB - PDF)

**First published:**

03/11/2008

**Last updated:**

19/12/2025

[View](/pl/documents/product-information/replagal-epar-product-information_pl.pdf)

português (PT) (280.41 KB - PDF)

**First published:**

03/11/2008

**Last updated:**

19/12/2025

[View](/pt/documents/product-information/replagal-epar-product-information_pt.pdf)

română (RO) (328.31 KB - PDF)

**First published:**

03/11/2008

**Last updated:**

19/12/2025

[View](/ro/documents/product-information/replagal-epar-product-information_ro.pdf)

slovenčina (SK) (336.68 KB - PDF)

**First published:**

03/11/2008

**Last updated:**

19/12/2025

[View](/sk/documents/product-information/replagal-epar-product-information_sk.pdf)

slovenščina (SL) (318.99 KB - PDF)

**First published:**

03/11/2008

**Last updated:**

19/12/2025

[View](/sl/documents/product-information/replagal-epar-product-information_sl.pdf)

Suomi (FI) (273.55 KB - PDF)

**First published:**

03/11/2008

**Last updated:**

19/12/2025

[View](/fi/documents/product-information/replagal-epar-product-information_fi.pdf)

svenska (SV) (271.66 KB - PDF)

**First published:**

03/11/2008

**Last updated:**

19/12/2025

[View](/sv/documents/product-information/replagal-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** VR/0000310907 17/12/2025

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Replagal : EPAR - All Authorised presentations

English (EN) (10.28 KB - PDF)

**First published:** 21/07/2006

**Last updated:** 11/11/2013

[View](/en/documents/all-authorised-presentations/replagal-epar-all-authorised-presentations_en.pdf)

[Other languages (23)](#file-language-dropdown-240)

български (BG) (34.23 KB - PDF)

**First published:**

21/07/2006

**Last updated:**

11/11/2013

[View](/bg/documents/all-authorised-presentations/replagal-epar-all-authorised-presentations_bg.pdf)

español (ES) (11.78 KB - PDF)

**First published:**

21/07/2006

**Last updated:**

11/11/2013

[View](/es/documents/all-authorised-presentations/replagal-epar-all-authorised-presentations_es.pdf)

čeština (CS) (30.29 KB - PDF)

**First published:**

21/07/2006

**Last updated:**

11/11/2013

[View](/cs/documents/all-authorised-presentations/replagal-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (11.69 KB - PDF)

**First published:**

21/07/2006

**Last updated:**

11/11/2013

[View](/da/documents/all-authorised-presentations/replagal-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (11.71 KB - PDF)

**First published:**

21/07/2006

**Last updated:**

11/11/2013

[View](/de/documents/all-authorised-presentations/replagal-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (11.63 KB - PDF)

**First published:**

21/07/2006

**Last updated:**

11/11/2013

[View](/et/documents/all-authorised-presentations/replagal-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (33.99 KB - PDF)

**First published:**

21/07/2006

**Last updated:**

11/11/2013

[View](/el/documents/all-authorised-presentations/replagal-epar-all-authorised-presentations_el.pdf)

français (FR) (11.7 KB - PDF)

**First published:**

21/07/2006

**Last updated:**

11/11/2013

[View](/fr/documents/all-authorised-presentations/replagal-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (29.78 KB - PDF)

**First published:**

21/07/2006

**Last updated:**

11/11/2013

[View](/hr/documents/all-authorised-presentations/replagal-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (11.73 KB - PDF)

**First published:**

21/07/2006

**Last updated:**

11/11/2013

[View](/is/documents/all-authorised-presentations/replagal-epar-all-authorised-presentations_is.pdf)

italiano (IT) (11.79 KB - PDF)

**First published:**

21/07/2006

**Last updated:**

11/11/2013

[View](/it/documents/all-authorised-presentations/replagal-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (32.67 KB - PDF)

**First published:**

21/07/2006

**Last updated:**

11/11/2013

[View](/lv/documents/all-authorised-presentations/replagal-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (27.54 KB - PDF)

**First published:**

21/07/2006

**Last updated:**

11/11/2013

[View](/lt/documents/all-authorised-presentations/replagal-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (20.5 KB - PDF)

**First published:**

21/07/2006

**Last updated:**

11/11/2013

[View](/hu/documents/all-authorised-presentations/replagal-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (28.52 KB - PDF)

**First published:**

21/07/2006

**Last updated:**

11/11/2013

[View](/mt/documents/all-authorised-presentations/replagal-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (11.7 KB - PDF)

**First published:**

21/07/2006

**Last updated:**

11/11/2013

[View](/nl/documents/all-authorised-presentations/replagal-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (11.67 KB - PDF)

**First published:**

21/07/2006

**Last updated:**

11/11/2013

[View](/no/documents/all-authorised-presentations/replagal-epar-all-authorised-presentations_no.pdf)

polski (PL) (85.36 KB - PDF)

**First published:**

21/07/2006

**Last updated:**

11/11/2013

[View](/pl/documents/all-authorised-presentations/replagal-epar-all-authorised-presentations_pl.pdf)

português (PT) (60.85 KB - PDF)

**First published:**

21/07/2006

**Last updated:**

11/11/2013

[View](/pt/documents/all-authorised-presentations/replagal-epar-all-authorised-presentations_pt.pdf)

slovenčina (SK) (81.27 KB - PDF)

**First published:**

21/07/2006

**Last updated:**

11/11/2013

[View](/sk/documents/all-authorised-presentations/replagal-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (18.1 KB - PDF)

**First published:**

21/07/2006

**Last updated:**

11/11/2013

[View](/sl/documents/all-authorised-presentations/replagal-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (12.06 KB - PDF)

**First published:**

21/07/2006

**Last updated:**

11/11/2013

[View](/fi/documents/all-authorised-presentations/replagal-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (11.69 KB - PDF)

**First published:**

21/07/2006

**Last updated:**

11/11/2013

[View](/sv/documents/all-authorised-presentations/replagal-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Replagal Active substance agalsidase alfa International non-proprietary name (INN) or common name agalsidase alfa Therapeutic area (MeSH) Fabry Disease Anatomical therapeutic chemical (ATC) code A16AB03

### Pharmacotherapeutic group

Other alimentary tract and metabolism products

### Therapeutic indication

Replagal is indicated for long-term enzyme-replacement therapy in patients with a confirmed diagnosis of Fabry disease (?-galactosidase-A deficiency).

## Authorisation details

EMA product number EMEA/H/C/000369 Marketing authorisation holder

Takeda Pharmaceuticals International AG Ireland Branch

Block 2 Miesian Plaza

Opinion adopted 29/03/2001 Marketing authorisation issued 03/08/2001 Revision 30

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Replagal : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (142.43 KB - PDF)

**First published:** 18/09/2025

**Last updated:** 19/12/2025

[View](/en/documents/procedural-steps-after/replagal-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

Replagal : EPAR - Procedural steps taken and scientific information after authorisation (archive)

English (EN) (2.81 MB - PDF)

**First published:** 03/11/2008

**Last updated:** 18/09/2025

[View](/en/documents/procedural-steps-after/replagal-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf)

Replagal : EPAR - Steps taken after authorisation when a cutoff date has been used

English (EN) (87.45 KB - PDF)

**First published:** 21/07/2006

**Last updated:** 21/07/2006

[View](/en/documents/steps-after-cutoff/replagal-epar-steps-taken-after-authorisation-when-cutoff-date-has-been-used_en.pdf)

## Initial marketing authorisation documents

Replagal : EPAR - Scientific Discussion

English (EN) (258 KB - PDF)

**First published:** 21/07/2006

**Last updated:** 21/07/2006

[View](/en/documents/scientific-discussion/replagal-epar-scientific-discussion_en.pdf)

Replagal : EPAR - Procedural steps taken before authorisation

English (EN) (88.43 KB - PDF)

**First published:** 21/07/2006

**Last updated:** 21/07/2006

[View](/en/documents/procedural-steps/replagal-epar-procedural-steps-taken-authorisation_en.pdf)

#### More information on Replagal

This product is no longer an orphan medicine. It was originally [designated an orphan medicine](/en/medicines/human/orphan-designations/eu300002) on 8 August 2000. Replagal was withdrawn from the Community register of orphan medicinal products in August 2011 at the end of the 10-year period of market exclusivity.

#### Topics

- [Medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A61)

**This page was last updated on** 19/12/2025

## Share this page

[Back to top](#main-content)